---
title: "Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298883242.md"
description: "Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)"
datetime: "2026-09-14T07:50:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298883242.md)
  - [en](https://longbridge.com/en/news/298883242.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298883242.md)
generator: "portal-rs"
---

# Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)


### Related Stocks

- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)
- [SRRK.US](https://longbridge.com/en/quote/SRRK.US.md)
- [DHR.US](https://longbridge.com/en/quote/DHR.US.md)

## Related News & Research

- [Integrated Wealth Concepts LLC Reduces Stock Position in Danaher Corporation $DHR](https://longbridge.com/en/news/299014788.md)
- [Danaher Announces Quarterly Dividend | DHR Stock News](https://longbridge.com/en/news/299092045.md)
- [Danaher Corp Stock (DHR) Closed Up by 3.01% on Sep 15: A Full Analysis](https://longbridge.com/en/news/299091853.md)
- [SRRK: ISEMBYLD receives FDA approval as the first muscle-targeted SMA therapy, launching in the U.S](https://longbridge.com/en/news/298774302.md)
- [Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy](https://longbridge.com/en/news/299079376.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**